[Featured Stock] Alteogen Targets 2nd Largest KOSDAQ Market Cap... Emphasizes Merck Subcutaneous Injection at ASCO Increase

Alteogen is showing strong performance and is aiming to surpass the 2nd place in KOSDAQ market capitalization. This is interpreted as being influenced by news that the subcutaneous injection (SC) formulation became a hot topic at the American Society of Clinical Oncology (ASCO).

As of 9:17 AM on the 7th, Alteogen is trading at 251,500 KRW, up 5.67% from the previous day. Its market capitalization is fluctuating around 13.3 trillion KRW, competing in ranking with Ecopro, which holds the 2nd place in KOSDAQ market capitalization.

According to the industry, MSD, the U.S. company that signed an exclusive contract with Alteogen for the development of the subcutaneous injection formulation of the blockbuster immuno-oncology drug Keytruda, emphasized the importance of subcutaneous injections at ASCO. MSD announced the results of a Phase 2b clinical trial combining Keytruda with Moderna’s messenger RNA (mRNA) vaccine, stating that “all indications acquired by Keytruda can be converted to the subcutaneous injection formulation.”

By suggesting that MSD can significantly expand the use of Keytruda’s subcutaneous injection, the possibility of a substantial increase in royalties from Alteogen’s technology transfer has emerged. Previously, Alteogen signed an exclusive license agreement with MSD, receiving an upfront payment of 20 million USD (approximately 26.7 billion KRW), along with milestones based on product approvals, patent extensions, and cumulative net sales of the product portfolio, and agreed to receive a certain percentage of net sales as royalties after product launch.

This content was produced with the assistance of AI translation services.